Patent application number | Description | Published |
20120328616 | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING BETA-KLOTHO AND AN FGF RECEPTOR - The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. | 12-27-2012 |
20140024111 | HOST CELL FOR MAKING ANTIBODY FC-HETERODIMERIC MOLECULES USING ELECTROSTATIC STEERING EFFECTS - The invention relates to methods of making Fc-heterodimeric proteins or polypeptides. The invention also relates to the Fc-heterodimeric proteins or polypeptides themselves, including the individual polypeptide components that comprise the heterodimer Nucleic acids encoding such polypeptides, expression vectors, and host cells. Moreover, the invention relates to pharmaceutical compositions comprising one of more Fc-heterodimeric proteins or polypeptides. | 01-23-2014 |
20140038285 | METHOD OF CORRELATED MUTATIONAL ANALYSIS TO IMPROVE THERAPEUTIC ANTIBODIES - A method of improving antibody manufacturability or developability through a computational approach. | 02-06-2014 |
20140112926 | Fc VARIANTS - Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins. | 04-24-2014 |
20140161828 | BCMA ANTIGEN BINDING PROTEINS - The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates. | 06-12-2014 |
20140286898 | INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS - Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells. | 09-25-2014 |
20140302036 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 - Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins. | 10-09-2014 |
20140343252 | INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS - Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells. | 11-20-2014 |
20140378665 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES - GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. | 12-25-2014 |